1. Home
  2. Analysis
  3. Ativan
  4. Primary-myelofibrosis

Ativan and Primary myelofibrosis - a phase IV clinical study of FDA data

Summary:

Primary myelofibrosis is reported as a side effect among people who take Ativan (lorazepam), especially for people who are female, 60+ old, also take Jakafi, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Primary myelofibrosis when taking Ativan. It is created by eHealthMe based on reports of 74,376 people who have side effects when taking Ativan from the FDA, and is updated regularly.

What is Ativan?

Ativan has active ingredients of lorazepam. It is often used in stress and anxiety. eHealthMe is studying from 78,506 Ativan users. Check the latest studies of Ativan.

What is Primary myelofibrosis?

Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 322 drugs and 841 conditions by eHealthMe. Check the latest studies of Primary myelofibrosis.

On Jul, 27, 2026

74,376 people reported to have side effects when taking Ativan.
Among them, 55 people (0.07%) have Primary myelofibrosis.

Could Ativan cause Primary myelofibrosis?

Among these 55 people:

What is the gender of people who have Primary myelofibrosis when taking Ativan? *

  • female: 73.53 %
  • male: 26.47 %

What is the age of people who have Primary myelofibrosis when taking Ativan? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 15.62 %
  • 50-59: 37.5 %
  • 60+: 46.88 %

What are other drugs people take besides Ativan? *

  1. Jakafi: 23 people, 41.82%
  2. Cymbalta: 18 people, 32.73%
  3. Motrin: 15 people, 27.27%
  4. Meclizine: 14 people, 25.45%
  5. Euthyrox: 14 people, 25.45%
  6. Flexeril: 13 people, 23.64%
  7. Amoxicillin: 11 people, 20.00%
  8. Lorazepam: 10 people, 18.18%
  9. Levothyroxine Sodium: 10 people, 18.18%
  10. Multivitamin: 6 people, 10.91%

What are other side effects people have besides Primary myelofibrosis? *

  1. Fatigue (feeling of tiredness): 38 people, 69.09%
  2. Dizziness: 35 people, 63.64%
  3. Pain In Extremity: 32 people, 58.18%
  4. Dyspnea (difficult or laboured breathing): 32 people, 58.18%
  5. Weight Increased: 30 people, 54.55%
  6. Hoarseness Or Changing Voice: 30 people, 54.55%
  7. Haemoglobin Decreased: 30 people, 54.55%
  8. Nausea (feeling of having an urge to vomit): 30 people, 54.55%
  9. Pain: 29 people, 52.73%
  10. Joint Pain: 28 people, 50.91%

What are the existing conditions these people have? *

  1. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 18 people, 32.73%
  2. Pelvic Pain: 17 people, 30.91%
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 17 people, 30.91%
  4. Neuropathy Peripheral (surface nerve damage): 17 people, 30.91%
  5. Thyroid Diseases: 14 people, 25.45%
  6. Sinusitis (inflammation of sinus): 14 people, 25.45%
  7. Muscle Spasms (muscle contraction): 7 people, 12.73%
  8. Pain: 5 people, 9.09%
  9. Iron Overload: 3 people, 5.45%
  10. Dizziness: 2 people, 3.64%

* Approximation only. Some reports may have incomplete information.

Do you take Ativan and have Primary myelofibrosis?

- Check whether Primary myelofibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ativan:

Primary myelofibrosis treatments and more:

How severe was Primary myelofibrosis and when was it recovered:

Expand to all the drugs that have ingredients of lorazepam:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ativan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Primary myelofibrosis:

Browse all the conditions that are associated with Primary myelofibrosis:

How the study uses the data?

The study uses data from the FDA. It is based on lorazepam (the active ingredients of Ativan) and Ativan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.